Диссертация (1141100), страница 19
Текст из файла (страница 19)
Juvenile idiopathic arthritis and malignancy.Rheumatology(Oxford,England)//rheumatology.oxfordjournals.org/content/early/2013/10/31/rheumatology.ket318; 2013 Oct 31.108. Ruperto N., Nikishina I., Pachanov E.D., et al. A randomized, doubleblind clinical trial of two doses of meloxicam compared with naproxen in childrenwith juvenile idiopathic arthritis: short- and long-term efficacy and safety results //Arthritis Rheum.
– 2005. – Vol. 52 – P.563–72.109. Saurenmann R.K., Rose J.B., Tyrrell P., et al. Epidemiology ofjuvenile idiopathic arthritis in a multiethnic cohort: Ethnicity as a risk factor //Arthritis & Rheumatism – 2007. – Vol.56 - P.1974–84.110. Schmeling H., Horneff G.
Etanercept and uveitis in patients withjuvenile idiopathic arthritis // Rheumatology. – 2005. – Vol.44. – P.1008-11.123111. Schmeling H., Minden K., Foeldvari I., et al. Efficacy and safety ofadalimumab as the first and second biologic agent in juvenile idiopathic arthritis:the German Biologics JIA Registry // Arthritis Rheumatol. – 2014 – Vol.66 –P.2580–9.112. Scott C., Meiorin S., Filocamo G., et al. A reappraisal of intraarticular corticosteroid therapy in juvenile idiopathic arthritis // Clin ExpRheumatol.
- 2010. – Vol.28. – P.774–81.113. Sen E.S., Dick A.D., Ramanan A.V. Uveitis associated with juvenileidiopathic arthritis // Nat Rev Rheumatol. – 2015. – Vol.11(6) – P.338–48.114. Simonini G, Druce K, Cimaz R et al. Curent evidence of anti-tumornecrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematicreview and meta-analysis approach of individual drugs// Arthritis Care Res (Hoboken)-2014; 66(7):1073-1084, doi:10.1002/acr22214.115.
Silverman E., Mouy R., Spiegel L., et al. Leflunomide or methotrexatefor juvenile rheumatoid arthritis// N Engl J Med. – 2005. – Vol.352:1655–66.116. Singh S., Bhattad S., Danda D. Genetics of juvenile idiopathic arthritis// Int J Rheum Dis. – 2014. – Vol. 17(3) – P.233-6.117. Singh Y.P., Singh A.K., Aggarwal A, et al.
Evidence of cellularimmune response to outer membrane protein of Salmonella typhimurium inpatients with enthesitis-related arthritis subtype of juvenile idiopathic arthritis// JRheumatol. – 2011. - Vol.38 – P. 161-6118. Smith J.A., Thompson D.J., Whitcup S.M., et al.: A randomized,placebo-controlled, double-masked clinical trial of etanercept for the treatment ofuveitis associated with juvenile idiopathic arthritis // Arthritis & RheumatismArthritis Care & Research – 2005.
– Vol.53 - P. 18-23.119. Srivastava R., Phatak S., Yadav A., et al. HLA B27 typing in 511children with juvenile idiopathic arthritis from India// Rheumatol Int.- 2016. –Vol. 36(10) – P.1407-11.124120. Tappeiner C., Mesquida M., Adan A., et al.: Evidence for Tocilizumabas a Treatment Option in Refractory Uveitis Associated with Juvenile IdiopathicArthritis// The Journal of rheumatology. – 2016. - Vol. 43(12) – P.
2183-8.121. Tappeiner C., Heinz C., Roesel M., Heiligenhaus A. Elevated laserflare values correlate with complicated course of anterior uveitis in patients withjuvenile idiopathic arthritis// ActaOphthalmol. – 2011. – Vol.89(6) – P.521–7.122. Tappeiner C., Miserocchi E., Bodaghi B., et al. Abatacept in theTreatment ofSevere, Longstanding, and Refractory Uveitis Associated withJuvenile Idiopathic Arthritis// The Journal of rheumatology. – 2015. – Vol. 42(4).
–P. 706-11123. Tarkiainen M., Tynjala P., Vahasalo P., et al. Occurrence of adverseevents in patients with JIA receiving biologic agents: long-term follow-up in areal-life setting// Rheumatology. -2015. – Vol.54(7) – P.1170–6.124. Van Rossum M.A, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in thetreatment of juvenile chronic arthritis: a randomized, double-blind, placebocontrolled, multicenter study Dutch Juvenile Chronic Arthritis Study Group //Arthritis Rheum. – 1998 – Vol.41 – P.808–16.125. Vazquez-Cobian L.B., Flynn T., Lehman T.J. Adalimumab therapyfor childhood uveitis // J Pediatr.
– 2006. - Vol. 149(4) – P.572-5.126. Vilaiyuk S., Soponkanaporn S., Jaovisidha S., et al. A retrospectivestudy on 158 Thai patients with juvenile idiopathic arthritis followed in a singlecenter over a 15-year period// Int J Rheum Dis. – 2011. - Vol.19. - P.1342–50.127. Villani A.P., Rouzaud M., Sevrain M.J.
Prevalence of undiagnosedpsoriatic arthritis among psoriasis patients: Systematic review and meta-analysis //Am AcadDermatol. – 2015. – Vol.73(2) – P.242-8.128. Viswanath V., Myles A., Dayal R., et al. Levels of Serum MatrixMetalloproteinase-3 Correlate with Disease Activity in the Enthesitis-relatedArthritis Category of Juvenile Idiopathic Arthritis // The Journal of Rheumatology.– 2011. – Vol.38 (11) – P.2482-87125129. Walscheid K., Hennig M., Heinz C., et al. Correlation between diseaseseverity and presence of ocular autoantibodies in juvenile idiopathic arthritisassociated uveitis // Invest Ophthalmol Vis Sci.
– 2014. – Vol. 55 – P.3447–53.130. Yokota S., Imagawa T., Mori M., et al. Long-term treatment ofsystemic juvenile idiopathic arthritis with tocilizumab: results of an open-labelextension study in Japan //Ann Rheum Dis 2013. – Vol.72 – P.627–8.131. Zannin M.E., Birolo C., Gerloni V., et al. Safety and Efficacy ofInfliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis:1-year Followup Data from the Italian Registry// The Journal of Rheumatology.
–2013. – Vol.40(1) – P.74-9132. Zulian F., Balzarin M., Falcini F., et al. Abatacept for Severe AntiTumor Necrosis Factor alpha Refractory Juvenile Idiopathic Arthritis-RelatedUveitis// Arthritis Care & Research. – 2010. - Vol.62 - P. 821-5.126.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
